The latest announcement is out from Medmira ( (TSE:MIR) ).
MedMira Inc. has announced a partnership with MediGroup, a major US healthcare group purchasing organization, to expand its market reach to over 44,000 healthcare providers. This collaboration will allow MedMira to offer its Reveal® G4 HIV rapid test, which is FDA approved and known for its quick and reliable results, to a broader audience, enhancing its industry positioning and providing significant growth opportunities.
More about Medmira
MedMira Inc. operates in the healthcare industry, specializing in the development and distribution of rapid diagnostic tests. Their primary product is the Reveal® G4 HIV-1/2 antibody rapid test, which is known for its speed and accuracy, utilizing MedMira’s patented Rapid Vertical Flow Technology.
YTD Price Performance: 4.55%
Average Trading Volume: 95,688
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$87.21M
See more insights into MIR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com